CD19 and agammaglobulinemia: Analysis of individual groups of patients with antibody deficiencies with near-normal immunoglobulin levels or hyperimmunoglobulinemia with or without EBV reactivation also showed that the most sensitive parameter was the assessment of CD86 expression on CD4+ and CD19+ (Figure 14), which may be considered potential marker molecules in the future.